Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments (IVHSP)

Program Overview

Tools exist to prevent new cases of hepatitis A, hepatitis B, and hepatitis C; to treat people living with hepatitis B; and to cure people living with hepatitis C. Yet new cases of viral hepatitis continue to rise, many people infected with viral hepatitis remain undiagnosed, and far too many viral hepatitis-related deaths occur in the United States each year. IVHSP supports integrated viral hepatitis surveillance and prevention programs in states, territories, and large cities in the United States over five years (2021–2026). It will support the capacity of states, territories, and large cities to detect and respond to viral hepatitis outbreaks; to collect and analyze data to inform the development and implementation of public health interventions to prevent and control viral hepatitis; and to support viral hepatitis elimination planning and maximize access to viral hepatitis prevention, testing, and treatment to reduce the burden of viral hepatitis in their jurisdictions.

Key Strategies:

Component 1: Core Viral Hepatitis Outbreak Response and Surveillance Activities (Outbreaks and Surveillance)

• 1.1: Develop, implement, and maintain a plan to rapidly detect and respond to outbreaks of hepatitis A, hepatitis B, and hepatitis C
• 1.2: Systematically collect, analyze, interpret, and disseminate data to characterize trends and implement public health interventions for hepatitis A, acute hepatitis B, and acute and chronic hepatitis C
• 1.3: Systematically collect, analyze, interpret, and disseminate data to characterize trends and implement public health interventions for chronic hepatitis B and perinatal hepatitis C (contingent on available funding)

Component 2: Core Viral Hepatitis Prevention Activities (Prevention)

• 2.1: Support viral hepatitis elimination planning and surveillance and maximize access to testing, treatment, and prevention
• 2.2: Increase access to hepatitis C and hepatitis B testing and referral to care in high-impact settings (contingent on available funding)
• 2.3: Improve access to services preventing viral hepatitis among people who inject drugs (PWID) (contingent on available funding)

Component 3: Special Projects—Prevention, Diagnosis, and Treatment Related to the Infectious Disease Consequences of Drug Use (Special Projects for PWID)

• 3.1: Improve access to services for people who inject drugs in settings disproportionately affected by drug use
• 3.2: Implement prevention services and interventions to address emerging issues related to drug use (contingent on available funding)

Expected outcomes include improved surveillance for viral hepatitis, increased stakeholder engagement in viral hepatitis elimination planning, and improved access to viral hepatitis prevention, diagnosis, and treatment among populations most at risk.

Map of Funded Jurisdictions

To achieve these outcomes, CDC is funding surveillance and prevention activities in 59 jurisdictions and is funding special projects related to the infectious disease consequences of drug use in 17 jurisdictions.

Program Details

IVHSP Supplement Funding

CDC-RFA-PS21-21030301SUPP23

Overview

This supplement supports the goals for Outbreaks and Surveillance (Component 1) and Prevention (Component 2) to more specifically: 1) increase the early detection and interruption of hepatitis C outbreaks and transmission clusters by routine review of surveillance data and by conducting laboratory testing (elements included in implementation of HCV outbreak response plans); and 2) increase hepatitis B (HBV) and hepatitis C (HCV) diagnosis and treatment by providing routine testing and linkage to prevention and treatment in high-impact settings.

Key Strategies

Supplemental Component (SC) 1: Integrating Genomic and Epidemiologic Surveillance for Outbreak Detection and Response

• SC1.1: Develop system for integrating genomic and epidemiologic surveillance for detection of HCV transmission clusters and for public health response in the jurisdiction
• SC1.2: Build jurisdictional capacity to integrate genomic surveillance into the existing epidemiological surveillance of HCV infections
• SC1.3: Assess effectiveness of integrated genomic and epidemiologic surveillance to improve identification of HCV transmission networks

Supplemental Component (SC) 2: Increasing Access to Hepatitis C and/or Hepatitis B Testing and Linkage to Care in High-Impact Settings

• SC2.1: Increase routine HCV and/or HBV testing in high-impact settings
• SC2.2: Provide counseling, linkage to treatment and referral to prevention services in high-impact settings
• SC2.3: Build public health laboratory capacity for HCV and/or HBV testing (optional)

Expected outcomes include improved outbreak response capacity through targeted prevention and control measures and increased access to complete HCV and/or HBV testing among persons receiving services in high-impact settings and increased linkage to treatment and care for people with HCV and/or HBV infection.

To achieve these outcomes, CDC has awarded supplemental funding for surveillance and prevention activities in two jurisdictions under Supplement Component 1 and in eight jurisdictions under Supplement Component 2.